Palatability of Angiotensin II Antagonists Among Nephropathic Children

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2007 Feb 17

PMID 17302913

Citations 8

Authors

Chiara M Meier

Giacomo D Simonetti

Silvia Ghiglia

Emilio Fossali

Patrizia Salice

Costanzo Limoni

Mario G Bianchetti

Affiliations

Soon will be listed here.

Abstract

What Is Already Known About This Subject: * Among children, medication palatability is crucial for adherence to therapeutic regimen. * Several studies have measured the palatability of antimicrobial suspensions in paediatric patients by means of a visual analogue scale palatability score.

What This Study Adds: * This is the first analysis comparing the taste and smell acceptability of angiotensin II receptor blockers among paediatric patients with kidney disease. * From the perspective of the child with kidney disease, the taste of pulverized candesartan is significantly superior to that of pulverized irbesartan, losartan, telmisartan or valsartan.

Aim: Angiotensin II receptor blockers are widely prescribed in kidney disease. Among children, medication palatability is crucial for adherence.

Methods: Taste and smell acceptability of five angiotensin II receptor blockers were compared among 21 nephropathic children using a visual analogue scale palatability score.

Results: The score assigned to pulverized tablets of candesartan cilexetil was significantly higher than that assigned to pulverized tablets of irbesartan, losartan, telmisartan and valsartan.

Conclusions: From the perspective of the nephropathic child, the taste of pulverized candesartan cilexetil is superior to that of irbesartan, losartan, telmisartan or valsartan.

Citing Articles

Antihypertensive agents: a long way to safe drug prescribing in children.

Siddiqi N, Shatat I Pediatr Nephrol. 2019; 35(11):2049-2065.

PMID: 31676933 PMC: 7515858. DOI: 10.1007/s00467-019-04314-7.

Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review.

Mistry P, Batchelor H Paediatr Drugs. 2017; 19(3):223-233.

PMID: 28413843 DOI: 10.1007/s40272-017-0223-7.

Clinical utility of valsartan in treatment of children and adolescents with high blood pressure.

Kaushik M, Mohiuddin S Adolesc Health Med Ther. 2014; 2:97-103.

PMID: 24600279 PMC: 3926775. DOI: 10.2147/AHMT.S13772.

Differences in taste between three polyethylene glycol preparations: a randomized double-blind study.

Lam T, Mulder C, Felt-Bersma R Patient Prefer Adherence. 2011; 5:423-6.

PMID: 21949605 PMC: 3176181. DOI: 10.2147/PPA.S22780.

Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

Baracco R, Kapur G Patient Prefer Adherence. 2011; 5:149-55.

PMID: 21573045 PMC: 3090375. DOI: 10.2147/PPA.S12166.

References

Nevins T . "Why do they do that?" The compliance conundrum. Pediatr Nephrol. 2005; 20(7):845-8. DOI: 10.1007/s00467-005-1926-5. View

Ellis D, Moritz M, Vats A, Janosky J . Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens. 2004; 17(10):928-35. DOI: 10.1016/j.amjhyper.2004.06.014. View

Israili Z . Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000; 14 Suppl 1:S73-86. DOI: 10.1038/sj.jhh.1000991. View

Shahinfar S, Cano F, Soffer B, Ahmed T, Santoro E, Zhang Z . A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005; 18(2 Pt 1):183-90. DOI: 10.1016/j.amjhyper.2004.09.009. View

Ellis D, Vats A, Moritz M, Reitz S, Jo Grosso M, Janosky J . Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr. 2003; 143(1):89-97. DOI: 10.1016/S0022-3476(03)00279-8. View

Holas C, Chiu Y, Notario G, Kapral D . A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years. Clin Ther. 2006; 27(12):1950-60. DOI: 10.1016/j.clinthera.2005.11.017. View

Gartenmann A, Fossali E, von Vigier R, Simonetti G, Schmidtko J, Edefonti A . Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int. 2003; 64(4):1450-4. DOI: 10.1046/j.1523-1755.2003.00238.x. View

Nunn T, Williams J . Formulation of medicines for children. Br J Clin Pharmacol. 2005; 59(6):674-6. PMC: 1884856. DOI: 10.1111/j.1365-2125.2005.02410.x. View

Franscini L, von Vigier R, Pfister R, Fossali E, Bianchetti M . Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002; 15(12):1057-63. DOI: 10.1016/s0895-7061(02)03083-2. View

10.

Simonetti G, von Vigier R, Konrad M, Rizzi M, Fossali E, Bianchetti M . Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol. 2006; 21(10):1480-2. DOI: 10.1007/s00467-006-0144-0. View

11.

Conlin P . Angiotensin II Antagonists in the Treatment of Hypertension: More Similarities Than Differences. J Clin Hypertens (Greenwich). 2001; 2(4):253-257. View

12.

Sakarcan A, Tenney F, Wilson J, Stewart J, Adcock K, Wells T . The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol. 2001; 41(7):742-9. DOI: 10.1177/00912700122010645. View